

Cancer Precision Medicine Forum

2-3 December 2019, Berlin



The conversations we have with C-level executives indicate that they are increasingly avoiding some of the biggest trade shows. The reason? – why compete with thousands of conference goers for key meetings and conversations? In contrast it seems there is a trend where business leaders find smaller, more targeted events a more fruitful way to foster fresh ideas and form new partnerships.

Cancer Precision Medicine Forum which is borne out of the success of our regional Precision Medicine Forums (Nordic, Benelux), provides just that environment.

The forum brings together the most senior experts from across Europe and beyond to provide a truly unique environment for meaningful interactions with those at the very forefront of precision oncology. With a strictly limited attendance we provide you with the opportunity to network with your peers rather than passing them in a huge expo centre on your way to the next session 20 rooms away! This more intimate setting allows for free flowing debate and interactions, and, feedback suggests, promotes greater collaboration – which many agree, is key to the success of precision medicine.

The multidisciplinary agenda will provide a platform for healthcare professionals, industry, patients groups, research, payers and Government to share their experiences and vision for a future of improved cancer patient outcomes. The two days comprise a combination of keynotes, panel discussions, workshops, interviews and plentiful networking covering a range of topics from bench to bedside (and back).

Speakers include:



Dr. Andreas Penk,
Oncology Regional
President International
Developed Markets,
Pfizer



Prof. Klaus Cichutek, PhD,
President, **Paul-Ehrlich-
Institut**



Prof. Andrew Biankin,
Regius Professor of Surgery,
Director, Wolfson Wohl
Cancer Research Centre,
University of Glasgow



Dr. Benedikt Westphalen,
Head of Molecular
Diagnostics and Therapy
Program and the
Molecular Tumour Board,
Comprehensive Cancer
Centre, **University
Hospital Munich**

Speakers from:



www.precisionmedicineforum.com

DAY 1 Programme - Monday 2nd December 2019

11.00

Registration and Refreshments

11.30

Welcome & Opening Remarks from the Chair

11.45

Session One

Examining the Influence of Current Regulatory & Policy Frameworks in Facilitating the Progress & Implementation of Precision Oncology

This opening session will discuss the backdrop of national regulatory and policy frameworks enabling the advancement of precision oncology, examining the barriers and possible solutions being found to overcome these. A panel of leading experts will share their own perspectives on the following points, followed by extended audience Q&A discussion.

- Identifying the current legal, regulatory and ethical obstacles restricting the advancement of precision medicine
- Exploring ways in which regulatory frameworks need to adapt to overcome these obstacles, and enable innovation and delivery, especially with regards to:
 - data access and sharing
 - the use of AI and machine learning in precision oncology
- Examining how the disease and drug classification and reimbursement system could change to enable a broader, biological approach
- Assessing the effectiveness of European Reference Networks and how these could be enhanced and aligned with national healthcare systems:
 - how close are we to enabling cancer treatment across borders?

Panellists:

Dr Tuula Helander, Senior Specialist, **Ministry of Social Affairs & Health** and Secretary General, **Finnish Cancer Institute**

Prof Dr Klaus Cichutek, President, **Paul-Ehrlich-Institut**

Dr Denis Lacombe, Director General, **European Organisation for Research and Treatment of Cancer (EORTC)**

Prof Dr Ulrik Lassen, Head of Department of Oncology, **Rigshospitalet**

13.00

Networking Lunch

14.00

Session Two

International Perspective - Examining Developments in Precision Oncology Internationally and the Lessons that can be Learnt for Effective Implementation within Europe

Dr Andreas Penk, Regional President Oncology International Developed Markets, **Pfizer**

15.10

Session Three

Advancing Precision Medicine Through Partnerships, Collaboration & Funding Initiatives

The effective implementation of precision medicine needs collaborative approaches, both national and cross-border. Identifying and bringing together different stakeholders, and finding appropriate financial mechanisms are key elements; as well as a need to encourage multi-institutional and cross-border collaboration and facilitate transparent and effective data-sharing. This session will explore what can, and is being, achieved through different European projects.

Panellists:

Prof Stefan Fröhling, Acting Managing Director, **National Center for Tumor Diseases (NCT)** Heidelberg & Head, Division of Translational Medical Oncology, **German Cancer Research Center (DKFZ)**

Prof Dr Nisar P. Malek, Medical Director, Center for Personalised Medicine (ZPM), **University Hospital Tübingen**

Dr John Rowell, Chief Operational Officer, **Cancer Core Europe**

16.00

Refreshments & Networking

16.25

Delegates move to their chosen roundtable session

Roundtable Discussion Session

This session is intended to give participants the opportunity to discuss a specific topic in a more informal, participative format. Delegates may choose one roundtable to attend, and each table will be led by a facilitator who will outline some structured points for discussion and encourage optimum debate and exchange of ideas.

A. Optimising Big Data, AI and E-Health Solutions to Advance Precision Medicine

B. Computational Biology for Drug Discovery: Leveraging Cancer Genomics Data to Aid Discovery of Novel Targets and Biomarkers

Dr Joshua Armenia, Senior Scientist Oncology Bioinformatics, **AstraZeneca**

C. Innovative Approaches to Clinical Trial Design

Prof Dr Kjetil Taskén, Head & Director, **Institute for Cancer Research - Norwegian Radium Hospital** and Group Leader, Dept of Cancer Immunology, **Oslo University Hospital**. Professor, Institute of Clinical Medicine, **University of Oslo**

D. Creating an Effective Learning Health System for Oncology Precision Medicine

Prof Brendan Delaney, Chair in Medical Informatics & Decision Making, Faculty of Medicine, Department of Surgery & Cancer, **Imperial College London**

E. Immuno-Oncology: Exploring Advances in Cancer Immunotherapies

F. Liquid Biopsy: Circulating Tumour DNA & Bloodborne Biomarkers as Diagnostic Tools

Dr Leticia De Mattos-Arruda, Principal Investigator & Group Leader Precision Oncology Research, **IRSICAIXA Foundation, Hospital Universitari Germans Trias i Pujol**

G. Making it a Reality: Implementing Precision Oncology into Clinical Practice

Prof Dr Ulrik Lassen, Head of Department of Oncology, **Rigshospitalet**

H. Overcoming Drug Resistance in Precision Oncology

17.30

Roundtable Feedback

Each roundtable facilitator will share the key learning points from their table discussion with the audience.

18.10

Close of Day One followed by a Complimentary Networking Drinks Reception

DAY 2 Programme - Tuesday 3rd December 2019

08.30

Welcome Refreshments & Networking

09.00

Opening Remarks from the Chair

09.10

Keynote Address: Advancing Precision Oncology - Priorities & Opportunities

09.30

Session Four

Innovations in Data Gathering & Effective Clinical Trial Design

A greater understanding of disease and the realisation that cancer can no longer be defined in basic terms, is having a significant impact on clinical trials and drug development. Innovations in clinical trial design, and better understanding how to classify patients, including selection for novel cancer immunotherapies, has the potential to accelerate research and drug development so that the right therapies can rapidly be delivered to the right patients.

However, new approaches to clinical trials and the development of precision oncology require a change in the approach to research and data-gathering, and its application to clinical practice. There is a growing need to analyse a broader range of clinical outcomes within research, treatment evaluation and reimbursement decisions. This session will explore the implications of re-thinking clinical trial design and some of the results already being achieved.

Panellists:

Prof Dr Jürgen Wolf, Medical Director, Centre for Integrated Oncology & Chair, Lung Cancer Programme, Dept. of Internal Medicine, **University Hospital of Cologne**

Prof Andrew V. Biankin, Regius Professor of Surgery, Director, **Wolfson Wohl Cancer Research Centre**, Executive Director, **International Cancer Genome Consortium**, Director, Glasgow Precision Oncology Laboratory, Chair, Precision-Panc Therapeutic Development Platform, **University of Glasgow**

Dr C. Benedikt Westphalen, Head, Molecular Diagnostics and Therapy Program and Molecular Tumor Board, CCC München – Comprehensive Cancer Center, **University Hospital Munich**

10.15

Refreshments & Networking

10.45

Session Five

Applying a Better Understanding of Tumour Molecular Heterogeneity & Evolution to Enable the Development of New Solutions in Oncology Clinical Practice

The understanding of tumour structure and evolution in cancer is fundamental to the advancement of precision oncology, enabling the identification of genomic alteration in key genes and pathways that can then be targeted with appropriate therapies. However molecular heterogeneity presents major challenges to effective cancer therapy and much effort is still needed to understand the molecular biology and clinical behaviour of heterogeneous and constantly evolving tumours and unravel the mechanisms of drug resistance in order to drive the development of effective precision strategies.

Panellists:

Dr Maud Kamel, Scientific Manager, Department of Drug Development and Innovation (D3i), **Institut Curie**

Prof Dr Kjetil Taskén, Head & Director, **Institute for Cancer Research - Norwegian Radium Hospital** and Group Leader, Dept of Cancer Immunology, Oslo University Hospital. Professor, Institute of Clinical Medicine, **Oslo University Hospital**

Prof Sibylle Mitnacht, Professor of Molecular Cancer Biology, **UCL Cancer Institute**

12.15

Session Six

The Economics of Precision Medicine – Achieving a Balance Between Establishing Value & Optimum Patient Care

A significant barrier to the advancement of precision medicine in practice is regarding economics, the perception of “value” and developing effective reimbursement mechanisms to meet the requirements of the payer. This session will examine the potential challenges encountered when demonstrating the economic case for precision oncology and assess the key criteria on which decisions on where to invest are made. It will also discuss solutions for deploying new evidence-based testing and technologies quickly and efficiently, and managing the difficult balance between value economics and optimum patient care.

Panellists:

Dr Bettina Ryll, Member, ESMO & Founder, **Melanoma Patient Network Europe**

Prof Dr Maarten J. Postma, Professor in Pharmacoeconomics, **Groningen Research Institute of Pharmacy** & Chair, Global Health Economics, **University Medical Centre Groningen**

Dr Gerhard Schillinger, Specialist in Neurosurgery & Head of Medical Staff, **AOK-Bundesverband**

13.00

Networking Lunch

14.00

Session Seven

Emerging Innovations to Achieve Advanced Oncology Diagnostics & Precision Treatment Options

This session will explore advances in, and the application of, innovative technologies and research developments, which can enable earlier cancer diagnosis as well as a wider range of precision treatment options and likely outcomes.

Exploring How to Move towards Precision Immunotherapy

Prof Dr Ulrich Keilholz, Professor of Medical Oncology & Director, **Charité Comprehensive Cancer Center**

Challenges, Opportunities and Newest Applications for Molecular Tumour Diagnostics

Dr Christian Ruiz, Head Diagnostic Laboratory Department, Medical Genetics & Pathology & Co-Director Research Department, Pathology, **Universitätsspital Basel**

Other innovations to be discussed include:

- Digital Pathology and Bioinformatics for Precision Oncology
- Innovations in Imaging Technology and Radiology
- Using Artificial Intelligence to Analyse & Predict the Behaviour of Cancer Cells
- Liquid Biopsy as a Precision Diagnostic Tool

16.00

Closing Remarks from the Chair and Close of Conference

Choose Your Delegate Package:

Conference Rate:

Standard Rate:

€800

(early bird discount just €550 until 4/11/2019)

Academia/Healthcare:

€460

(early bird discount just €300 until 4/11/2019)

Fee includes:

- Conference Pass
- Delegate Programme
- Buffet lunch, snacks and refreshments throughout the conference
- Complimentary Networking Drinks Reception

How to Register:

1. Online through our secure portal: Register and pay online www.precisionmedicineforum.com (you will need your payment card to complete registration)
2. Complete the registration form www.precisionmedicineforum.com and we will send an invoice (please note your place is not confirmed until full payment is received)
3. Phone: +44 (0)1273 931616
4. Email: register@precisionmedicineforum.com

Venue:

**Estrel Berlin
Sonnenallee 225
12057 Berlin,
Germany**

Marketing Opportunities:

We believe that connecting with other leading minds is the best way to grow your brand and business.

The format of Precision Medicine Forum offers a unique environment to make new connections, share ideas and formulate partnerships for future collaboration. As a sponsor we work with you to ensure that your objectives are met by building bespoke packages. These can range from exhibition stands to hosting workshops, sponsorship of gala dinners to playing your corporate video during a break.

- ✓ Build your brand presence
- ✓ Demonstrate your expertise and thought leadership
- ✓ Showcase your products and services
- ✓ Generate new business leads
- ✓ Align yourself with the leading organisations in the Precision Medicine arena

Don't forget, – it's not just about the conference itself. As a sponsor you'll be afforded considerable marketing exposure across a whole variety of channels before, during and post event through Precision Medicine Forum online, via our social media and affiliates.

**For further information please contact us: marketing@precisionmedicineforum.com
Tel: +44 (0)1273 931616**